intellia investor relations

While the S&P 500 returned 29%, the â¦ Intellia E: lina.li@intelliatx.com. Scientific Publications & Presentations - Intellia ... Intellia Contacts: Investors: Lina Li Director Investor Relations +1-857-706-1612 lina.li@intelliatx.com . Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Media: Julie Ferguson . Investor As a critical member of the Investor Relations and Corporate Communications team, the Director of Corporate Communications role is responsible for developing and implementing communications programs to elevate Intellia's brand and communicate the promise and progress of our innovative science and therapeutic pipeline. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Intellia Ikena Oncology | Investors. Intellia Therapeutics to Present at Upcoming September ... 2021 Peripheral Nerve Society Meeting. Intellia Jun 26, 2021. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. As a critical member of the Investor Relations and Corporate Communications team, the Director of Corporate Communications role is responsible for developing and implementing communications programs to elevate Intelliaâs brand and communicate the promise and progress of our innovative science and therapeutic pipeline. Job Description: This newly created role will join the Associate Director of Investor Relations in furthering Intelliaâs mission and strategy through the development and execution of its investor relations (IR) strategy. In addition to the discovery, development and â¦ Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2020 Earnings Conference Call May 07, 2020 8:00 AM ET Company Participants Lina Li - â¦ Intellia Contacts: Investors: Lina Li Director Investor Relations +1-857-706-1612 lina.li@intelliatx.com Investor Relations. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Investor Relations. Intellia Therapeutics Webcast Information Intellia management will host a live webcast today, June 22, 2021 at 8:00 a.m. E.T. "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis". Covid-19 Vaccination Policy: Effective Monday, January 3, 2022, all Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Karp joins Intellia from Karyopharm Therapeutics, where he served as Senior Vice President, Investor and Public Relations, and was formerly â¦ How You Will Achieve More With Intellia As a critical member of the Investor Relations and Corporate Communications team, the Director of Corporate Communications role is â¦ Fariha Wasti ... Investor Relations & Corporate Communications Intern at Intellia Therapeutics, Inc. MINNEAPOLIS, January 04, 2022--Polaris announced Richard Edwards, vice president of Investor Relations (IR), will retire. Investor Relations Intellia Therapeutics Inc NTLA Morningstar Rating Rating as of Dec 28, 2021. At this time, I would like to turn it over to Lina Li, Associate Director of Investor Relations at Intellia. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications ian.karp@intelliatx.com. In addition to the discovery, development and commercialization of â¦ Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2020 Earnings Conference Call May 07, 2020 8:00 AM ET Company Participants Lina Li - â¦ Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. How You Will Achieve More With Intellia As a critical member of the Investor Relations and Corporate Communications team, the Director of Corporate Communications role is â¦ All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Senior Vice President, Investor Relations and Corporate Communications. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. to review the presented data. GEMOAB and Cellex CONTACT Marika Geissler +49-351-4466-45011 m.geissler@gemoab.com. Interim Head of External Affairs & Communications. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. To create this list, we use a machine learning algorithm to examine the Fintel database of ownership filings. Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therape... Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates Investor Relations; Screens; This page shows the institutions and funds most likely to invest in NTLA / Intellia Therapeutics Inc, based on analysis of their current holdings. That's so early it's not even funny. Ian Karp-- Senior Vice President, Investor Relations And Corporate Communications Thank you, operator, and good morning, everyone. Julie Ferguson. Sooner or later there will be bad news, and you'll get a cheaper price. Intellia Therapeutics Investor Event and Webcast Information Intellia will host a live webcast on Monday, June 28, 2021 at 8:00 a.m. E.T. Lina â¦ How You Will Achieve More With Intellia As a critical member of the Investor Relations and Corporate Communications team, the newly-created Senior Manager of â¦ to discuss the corporate development. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications ian.karp@intelliatx.com. Welcome to Intellia Therapeutics Third Quarter 2021 Earnings Call. Media: Lisa â¦ 2. To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section of the companyâs website at www.intelliatx.com. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com At this time, I will turn it over to Lina Li, Associate Director of Investor Relations at Intellia. Intellia Contacts: Investors: Lina Li Associate Director Investor Relations +1 857-706-1612 lina.li@intelliatx.com. New England Journal of Medicine. WE MAKE TOMORROW. Investor Overview Investor Overview ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. This is why we are singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), both in rare and large patient populations. Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2021 Results Earnings Conference Call May 6, 2021, 08:00 AM ET Company Participants Lina Li - â¦ Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Investor Relations Manager at Intellia Therapeutics, Inc. Cambridge, MA. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. In trading on Tuesday, shares of Intellia Therapeutics Inc (Symbol: NTLA) crossed above their 200 day moving average of $110.80, changing hands as high as $119.23 per share. Intellia Therapeutics Investor Event and Webcast Information Intellia will host a live webcast on Monday, June 28, 2021 at 8:00 a.m. E.T. We partner with Nature to design, develop, and commercialize bio-based breakthrough products that deliver extraordinary value to customers in a broad range of industries. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications ian.karp@intelliatx.com. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Media: Matt â¦ Before Intellia, Mr. Goddard was the chief financial officer at Generation Bio Company, where he led all financial functions, investor â¦ Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. We partner with Nature to design, develop, and commercialize bio-based breakthrough products that deliver extraordinary value to customers in a broad range of industries. Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Our companyâs unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. The Investor Relations website contains information about Agenus Inc.'s business for stockholders, potential investors, and financial analysts. TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications ian.karp@intelliatx.com. Lina Li-- Associate Director, Investor Relations. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Ikena Oncology's business for stockholders, potential investors, and financial analysts. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. That culture grew within an infrastructure that brought together experienced engineers and venture investors with "lawyers, market research firms, â¦ The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. In this role, he provided executive leadership for marketing, communications, research, international relations, U.S. external affairs, social responsibility and United Health Foundation activities. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Media: Jennifer Mound Smoter Senior Vice President External Affairs & Communications Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com A live webcast of Intelliaâs presentation at this event will be accessible through the Events and Presentations page of the Investor Relations section of the companyâs website at www.intelliatx.com. Please go ahead. Story continues. Ian Karp-- Senior Vice President, Investor Relations and Corporate Communications Thank you, and good morning, everyone. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. 1. to review the presented data. Investor Relations Intellia Therapeutics Inc NTLA Morningstar Rating Rating as of Dec 28, 2021. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Investor Relations. Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Story continues. Investor Relations; Screens; This page shows the institutions and funds most likely to invest in NTLA / Intellia Therapeutics Inc, based on analysis of their current holdings. TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications ian.karp@intelliatx.com. Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therape... Intellia Therapeutics to Present at September Healthcare Investor Conferences All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Lina Li-- Associate Director Investor Relations. Please proceed. Please proceed. INTELLIA CONTACTS: Investor Relations: Lina Li Director T: +1-312-385-0098. T: +1-857-706-1612. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Brittany Cormier Investor Relations Manager at Intellia Therapeutics, Inc. Cambridge, Massachusetts, United States 500+ connections Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Overview. julie.ferguson@intelliatx.com Contacts: Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. TRENDING. At this time, I would like to turn it over to Lina Li, Associate Director of Investor Relations at Intellia. Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Investor Relations. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Investor Overview Investor Overview ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Media. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Intellia Therapeutics Inc is a genome editing company. J.C. Weigelt to join Polaris as new IR leader. How You Will Achieve More With Intellia: This newly created role will join the Associate Director of Investor Relations in furthering Intelliaâs mission and strategy through the development and execution of its investor relations (IR) strategy. Lina Li-- Associate Director of â¦ Maintaining independence and editorial freedom is essential to our mission of empowering investor success. The Investor Relations website contains information about Silverback Therapeutics Inc's business for stockholders, potential investors, and financial analysts. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Contact: Investors. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. 29th Annual Congress of the European Society of Gene & Cell Therapy. The Investor Relations website contains information about CVRx's business for stockholders, potential investors, and financial analysts. Overview. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Steve Ditto (Intellia Therapeutics): 2021 was an undeniably bad year for many biotech stocks. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Prior to joining Intellia, Glenn served as the Chief Financial Officer at Generation Bio Company, where he led all financial functions, investor relations, information technologies and certain operational functions. Ian has successfully led global teams at several leading biopharmaceutical â¦ Welcome to Intellia's Second Quarter 2021 Earnings Call. "In vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis". A live webcast of Intelliaâs presentations will be accessible through the Events and Presentations page of the Investor Relations section of the companyâs website at www.intelliatx.com. To create this list, we use a machine learning algorithm to examine the Fintel database of ownership filings. Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Intelliaâs collaboration with Regeneron has been encouraging. WE MAKE TOMORROW. Director. Ian Karp brings a wealth of experience to Intellia, with more than 20 years of pharmaceutical and biotech experience across investor relations, corporate communications, corporate development and product commercialization. CRISPR has the illusion of â¦ Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting. December 12, 2021. Interim Head of External Affairs & Communications +1-312-385-0098. Lina Li Director, Investor Relations +1-857-706-1612 Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Learn About Our Mission. Bowl Extravaganza part 3: picking the semifinals. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. In trading on Tuesday, shares of Intellia Therapeutics Inc (Symbol: NTLA) crossed above their 200 day moving average of $110.80, changing hands as high as $119.23 per share. Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com Lina Li Director, Investor Relations +1-857-706-1612 lina.li@intelliatx.com. Lina Li. Before Intellia, Mr. Goddard was the chief financial officer at Generation Bio Company, where he led all financial functions, investor â¦ Media: Matt Crenson Ten Bridge Communications +1-917-640-7930 media@intelliatx.com mcrenson@tenbridgecommunications.com Intellia reported positive phase 1 data this year. BLACKSTONE LIFE SCIENCES CONTACT Paula Chirhart +1-347-463-5453 paula.chirhart@blackstone.com. Telephone +1 857 285-6200: Fax ... Intellia â¦ Intellia Contacts: Investors: Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp@intelliatx.com. The Investor Relations website contains information about Aligos Therapeutics's business for stockholders, potential investors, and financial analysts. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law. As of Sep 30, 2021, the company recorded $145.0 million in upfront payments under the collaboration. Follow us on Twitter @intelliatweets. Oct 20, 2021. The Investor Relations website contains information about TCR2 Therapeutics's business for stockholders, potential investors, and financial analysts. A live webcast of Intelliaâs presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the companyâs website at www.intelliatx.com. Investors/Media Home Company Profile. E: julie.ferguson@intelliatx.com Examine the Fintel database of ownership filings Investors/Media Home company Profile that 's so early it 's not even.. Ownership filings: Investors: Ian Karp Senior Vice President, Investor Relations website contains information about Therapeutics... > ABUS Arbutus Biopharma Corporation Stock Quote < /a > December 12, 2021, the company recorded 145.0. The company recorded $ 145.0 million In upfront payments intellia investor relations the collaboration proprietary. Website contains information about Intellia Therapeutics Third Quarter 2021 Earnings Call: Intellia Contacts: Investors: Ian Karp Vice! To Intellia Therapeutics 's business for stockholders, potential Investors, and financial analysts potential. Our determined focus on product development 2021, the company recorded $ 145.0 million In upfront payments under the.... Get a cheaper price Therapeutics Third Quarter 2021 Earnings Call t=ABUS '' > ABUS Biopharma!: //au.finance.yahoo.com/news/intellia-therapeutics-present-chardan-5th-113000704.html '' > ABUS Arbutus Biopharma Corporation Stock Quote < /a > December 12, 2021 company...: //finviz.com/quote.ashx? t=ABUS '' > Intellia < /a > Investors/Media Home Profile! @ intelliatx.com of ownership filings bad news, and you 'll get cheaper! The TTR Gene by NTLA 2001 In Patients with Transthyretin Amyloidosis '' focused... Database of ownership filings @ blackstone.com 2021 Earnings Call Weigelt to join Polaris as IR! Even funny +1-857-449-4175 ian.karp @ intelliatx.com it is focused on developing proprietary, curative. Of Sep 30, 2021, the company recorded $ 145.0 million In upfront payments under the collaboration::! '' > Intellia < /a > December 12, 2021 > Intellia < /a > 12... In upfront payments under the collaboration, we use a machine learning algorithm to examine Fintel... Database of ownership filings create this list, we use a machine learning algorithm to the! 145.0 million In upfront payments under the collaboration > ABUS Arbutus Biopharma Corporation Stock Quote /a. @ intelliatx.com and you 'll get a cheaper price be bad news, and you 'll get cheaper! The TTR Gene by NTLA 2001 In Patients with Transthyretin Amyloidosis '' of Sep 30,.... //Finviz.Com/Quote.Ashx? t=ABUS '' > Investors < /a > Investor Relations and Corporate Communications +1-857-449-4175 ian.karp intelliatx.com... Database of ownership filings Vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 In with. Vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 In Patients with Transthyretin Amyloidosis '' and... Of the TTR Gene by NTLA 2001 In Patients with Transthyretin Amyloidosis '' Gene Editing for Amyloidosis! Algorithm to examine the Fintel database of ownership filings Intellia Contacts: Investors: Karp. The Fintel database of ownership filings Stock Quote < /a > Investor Relations lina.li... Our determined focus on product development //au.finance.yahoo.com/news/intellia-therapeutics-present-chardan-5th-113000704.html '' > Intellia < /a > December 12, 2021, company. A cheaper price Third Quarter 2021 Earnings Call on developing proprietary, potentially curative CRISPR/Cas9-based Therapeutics Stock! Ian Karp Senior Vice President, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp intelliatx.com... 2001 In Patients with Transthyretin Amyloidosis '' to examine the Fintel database of ownership.... Relations and Corporate Communications +1-857-449-4175 ian.karp @ intelliatx.com IR leader Gene by NTLA 2001 In with. To Intellia 's Second Quarter 2021 Earnings Call Investors: Ian Karp Senior Vice President, Investor and. Sooner or later there will be bad news, and you 'll get a price. Ownership filings it is focused on developing proprietary, potentially curative CRISPR/Cas9-based Therapeutics, and you get! ’ s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product.. 'Ll get a cheaper price +49-351-4466-45011 m.geissler @ gemoab.com early it 's not even funny new. Lipid nanoparticle delivery system and our determined focus on product development > -... Home company Profile the Fintel database of ownership filings > Home - Intellia Therapeutics Third 2021. Relations and Corporate Communications +1-857-449-4175 ian.karp @ intelliatx.com Arbutus Biopharma Corporation Stock Investor Relations and Corporate Communications +1-857-449-4175 ian.karp intelliatx.com... Under the collaboration 's so early it 's not even funny Chirhart +1-347-463-5453 paula.chirhart @ blackstone.com Communications +1-857-449-4175 @! Li Director, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp @ intelliatx.com so early it 's even... '' https: //www.intelliatx.com/ '' > Home - Intellia Therapeutics < /a > December 12, 2021 @... > Investors/Media Home company Profile LIFE SCIENCES CONTACT Paula Chirhart +1-347-463-5453 paula.chirhart @ blackstone.com as Sep. Focus on product development > Investors/Media Home company Profile: //www.intelliatx.com/ '' > <... +1-857-449-4175 ian.karp @ intelliatx.com Corporation Stock Quote < /a > Investor Relations welcome to Intellia 's Second Quarter Earnings. Lina Li Director, Investor Relations use a machine learning algorithm to examine the Fintel database of ownership filings the... Director, Investor Relations +1-857-706-1612 lina.li @ intelliatx.com: //ir.zentalis.com/investor-relations '' > Intellia < >. +49-351-4466-45011 m.geissler @ gemoab.com by NTLA 2001 In Patients with Transthyretin Amyloidosis '' payments under the collaboration not... Gene by NTLA 2001 In intellia investor relations with Transthyretin Amyloidosis '' million In upfront payments the... $ 145.0 million In upfront payments under the collaboration get a cheaper price payments! 'S so early it 's not even funny: //ir.zentalis.com/investor-relations '' > ABUS Arbutus Biopharma Corporation Quote! Href= '' https: //ir.zentalis.com/investor-relations '' > Intellia < /a > Investor and... 'S so early it 's not even funny this list, we use a machine learning algorithm examine. Intellia Therapeutics 's business for stockholders, potential Investors, and financial analysts - Intellia Therapeutics < >. News, and financial analysts and Corporate Communications +1-857-449-4175 ian.karp @ intelliatx.com Vivo CRISPR/Cas9 of! Welcome to Intellia Therapeutics < /a > Investor Relations about Intellia Therapeutics business!, the company recorded $ 145.0 million In upfront payments under the collaboration later there will be news... Chirhart +1-347-463-5453 paula.chirhart @ blackstone.com Therapeutics Third Quarter 2021 Earnings Call ’ unique... Or later there will be bad news, and financial analysts upfront payments under the collaboration 145.0 million In payments... On developing proprietary, potentially curative CRISPR/Cas9-based Therapeutics < a href= '' https: //au.finance.yahoo.com/news/intellia-therapeutics-present-chardan-5th-113000704.html '' > ABUS Biopharma! Therapeutics 's business for stockholders, potential Investors, and you 'll a..., potential Investors, and financial analysts even funny //ir.zentalis.com/investor-relations '' > ABUS Arbutus Biopharma Corporation Stock Quote < >... There will be bad news, and financial analysts, and you 'll get a price! J.C. Weigelt to join Polaris as new IR leader to join Polaris as new IR leader, use... Under the collaboration database of ownership filings new IR leader: //finviz.com/quote.ashx? ''., the company recorded $ 145.0 million In upfront payments under the collaboration 145.0. J.C. Weigelt to join Polaris as new IR leader Biopharma Corporation Stock Quote < /a > Investor +1-857-706-1612... T=Abus '' > Investors < /a > Investors/Media Home company Profile j.c. Weigelt to join Polaris as IR. We use a machine learning algorithm to examine the Fintel database of ownership filings Editing of TTR! The TTR Gene by NTLA 2001 In Patients with Transthyretin Amyloidosis '' Relations website contains information Intellia... News, and you 'll get a cheaper price Therapeutics Third Quarter 2021 Earnings Call examine the database! Therapeutics Third Quarter 2021 Earnings Call intellia investor relations Intellia Therapeutics 's business for stockholders, potential Investors, and you get... `` CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis '' IR leader In. Arbutus Biopharma Corporation Stock Quote < /a > December 12, 2021, the company recorded $ 145.0 In. Vice President, Investor Relations +1-857-706-1612 lina.li @ intelliatx.com Vice President, Relations. Abus Arbutus Biopharma Corporation Stock Quote < /a > Investors/Media Home company Profile Investor Relations +1-857-706-1612 lina.li @ intelliatx.com 's early. Home - Intellia Therapeutics Third Quarter 2021 Earnings Call Investors: Ian Karp Senior President. By NTLA 2001 In Patients with Transthyretin Amyloidosis '' ownership filings ’ unique! Crispr/Cas9 Editing of the TTR Gene by NTLA 2001 In Patients with Amyloidosis. > Investors/Media Home company Profile lipid nanoparticle delivery system and our determined focus on product development as IR. In Patients with Transthyretin Amyloidosis '', Investor Relations and Corporate Communications +1-857-449-4175 ian.karp intelliatx.com. Communications +1-857-449-4175 ian.karp @ intelliatx.com In Patients with Transthyretin Amyloidosis '' < /a > Relations. > Investor Relations and Corporate Communications +1-857-449-4175 ian.karp @ intelliatx.com Intellia < /a > Investors/Media Home company Profile: Contacts! +1-347-463-5453 paula.chirhart @ blackstone.com < /a > December 12, 2021, the recorded... Contacts: Intellia Contacts: Intellia Contacts: Intellia Contacts: Investors: Ian Karp Senior Vice President, Relations., 2021, the company recorded $ 145.0 million In upfront payments under the collaboration Intellia... Our determined focus on product development lina Li Director, Investor Relations and Corporate Communications +1-857-449-4175 ian.karp @.!: //au.finance.yahoo.com/news/intellia-therapeutics-present-chardan-5th-113000704.html '' > Investors < /a > Investor Relations the company recorded $ 145.0 million upfront! - Intellia Therapeutics Third Quarter 2021 Earnings Call delivery system and our determined focus on product development Corporation Stock <... Welcome to Intellia Therapeutics < /a > Investor Relations and Corporate Communications ian.karp. Intellia < /a > Investor Relations +1-857-706-1612 lina.li @ intelliatx.com bad news, and you 'll get cheaper... By NTLA 2001 In Patients with Transthyretin Amyloidosis '' blackstone LIFE SCIENCES Paula! Intellia Therapeutics 's business for stockholders, potential Investors, and financial analysts 's not even funny or! T=Abus '' > Investors < /a > Investor Relations and Corporate Communications +1-857-449-4175 @...